Intrasubject Variability of Inhaled Insulin in Type 1 Diabetes: A Comparison with Subcutaneous Insulin

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Diabetes Technology & Therapeutics

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/1520915041705974PMID 15321001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhaled insulin

  2005cited by this paper
• Therapeutic insulins and their large-scale manufacture

  2005cited by this paper
• Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.

  2004cited by this paper
• Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.

  2003cited by this paper
• The impact of smoking on inhaled insulin.

  2003cited by this paper
• Pulmonary Insulin Administration Using the AERx® Insulin Diabetes System

  2002cited by this paper
• Intra-Subject Variability of Pulmonary Insulin via the AERx® Insulin Diabetes Management System Versus Subcutaneous Insulin

  2002cited by this paper
• Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.

  2002cited by this paper
• Physiological consequences of phasic insulin release in the normal animal.

  2002cited by this paper
• Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients

  2001cited by this paper
• Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery.

  2001cited by this paper
• Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial.

  2001cited by this paper
• Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33.

  2000cited by this paper
• Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler.

  2000cited by this paper
• Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.

  2000cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.

  1998cited by this paper
• Drug Delivery via the Respiratory Tract

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.

  1991cited by this paper
• The Variability in the Action of Unmodified Insulin is More Dependent on Changes in Tissue Insulin Sensitivity than on Insulin Absorption

  1988cited by this paper
• Insulin Pharmacokinetics

  1984cited by this paper
• Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures

  1981cited by this paper

• Review on Study of A Novel Insulin Delivery Method for the Treatment of Diabetes

  2023cites this paper
• Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

  2021cites this paper
• Inhaled insulin

  2020cites this paper
• The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma.

  2010cites this paper
• Safety and efficacy of inhaled insulin (AERx® iDMS 1 ) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1‐year data from a randomized, parallel group trial

  2009cites this paper
• Inhaled Insulin as alternative delivery system for subjects with diabetes – A literature review

  2009cites this paper
• Current therapies and technological advances in aqueous aerosol drug delivery.

  2008cites this paper
• Current Therapies and Technological Advances in Aqueous Aerosol Drug Delivery

  2008cites this paper
• Inhaled Technosphere® Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes

  2008cites this paper
• Inhaled insulin.

  2007cites this paper
• Current challenges in non-invasive insulin delivery systems: a comparative review.

  2007cites this paper
• First approved inhaled insulin therapy for diabetes mellitus

  2007cites this paper
• Delivering Needle-Free Insulin Using AERx® iDMS (Insulin Diabetes Management System) Technology

  2007cites this paper
• Insulin Therapy in Adults with Type 1 Diabetes Mellitus

  2007cites this paper
• Inhaled insulin: where are we and where might we go?

  2007cites this paper
• Inhaled insulin using AERx® insulin Diabetes Management System (AERx® iDMS)

  2007cites this paper
• Alternatives routes of insulin delivery.

  2006cites this paper
• Inhaled human insulin: a clinical perspective

  2006cites this paper
• Diabetes therapy trials with inhaled insulin

  2006cites this paper
• Clinical evaluation of inhaled insulin.

  2006cites this paper
• Neue Formen der Insulinapplikation

  2006cites this paper
• Inhaled insulin (Exubera®): combining efficacy and convenience

  2006cites this paper
• Review: Inhaled insulin: overcoming barriers to insulin therapy?

  2006cites this paper
• Inhaled human insulin: an inspiration for patients with diabetes mellitus?

  2006cites this paper
• Therapeutic insulins and their large-scale manufacture

  2005cites this paper
• Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

  2005cites this paper
• Inhaled insulin

  2005cites this paper
• Review: Current status of the development of inhaled insulin

  2004cites this paper